Bookmark and Share

Michael  Miller

Michael Miller M.D., F.A.C.C., F.A.H.A.

Academic Title: Professor
Primary Appointment: Medicine
Secondary Appointments: Epidemiology & Public Health
Additional Title(s): Director, Center for Preventive Cardiology
Location: UMMC, Room S3B06
Phone: (410) 328-6299
Fax: (410) 328-4382

Personal History:

Dr. Miller serves as Professor of Medicine in the Division of Cardiology and Professor of Epidemiology and Preventive Medicine at the University of Maryland School of Medicine. In addition, he is Director, Center for Preventive Cardiology for the University of Maryland Medical System and Staff Physician at the Veterans Affairs Medical Center in Baltimore. His major research interests are disorders of lipid and lipoprotein metabolism, molecular studies of HDL cholesterol, triglycerides and the postprandial response to dietary fat, nontraditional coronary risk factors and clinical trials to reduce atherosclerosis.

He received his B.A. degree from Rutgers College and his M.D. from The Robert Wood Johnson Medical School in New Jersey.  Following a medical residency at the University of Cincinnati Medical Center, he completed two fellowships at The Johns Hopkins Hospital in Baltimore, one in lipoprotein metabolism and the second in cardiovascular disease. Dr. Miller is a Fellow of the American College of Cardiology and the American Heart Association Council on Arteriosclerosis. He is Past President of the American Society of Preventive Cardiology and his research has been supported by the National Institutes of Health, the American Heart Association and Veterans' Affairs Administration.

Dr. Miller has been listed in “15 Top Cardiologists”  (Baltimore Magazine),  "Most Influential Physicians" (USA Today), "Super Doctors" (Washington Post) and "America's Top Doctors" (U.S. News and World Report in partnership with Castle Connolly Medical Ltd). He has served as a consultant to the National Library of Medicine and the U.S. Postal Service for the forever stamp "Heart Health". Since 2010, Dr. Miller has served on the Board of Trustees for the AstraZeneca HealthCare Foundation “Connections for Cardiovascular Health”, a charitable organization supporting communities through health connections.  In 2013, he was appointed by the Governor of Maryland, Martin O’Malley, to the State Advisory Council on Heart Disease and Stroke Prevention and on July 1, 2014 was appointed to serve as a Member of the American Heart Association Nutrition Committee of the Lifestyle and Cardiometabolic Health Council. Dr. Miller is board certified in Internal Medicine, Clinical Lipidology and Cardiovascular Disease. 

Dr. Miller is the author of the new book "Heal Your Heart-The Positive Emotions Prescription to Prevent and Reverse Heart Disease" (Rodale Press) based on his 23 years of patient care, experiences and research conducted at the University of Maryland School of Medicine.

Grants and Contracts:

Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides and Impact on Global Health outcomes (AIM-HIGH); Multicenter; National Heart, Lung, Blood Institute 2006-2012

IMPROVE-IT: Does lowering LDL and CRP with ezetimibe reduce cardiac Events; Multicenter; Merck-Schering Plough (2007-2011)

Dalcetrapib and Statin therapy versus statin monotherapy after Acute Coronary Syndromes; Multicenter; Roche (2008-2012)

The Effects of Ezetimibe/Simvastatin versus Simvastatin alone on Platelet and Inflammatory Biomarkers in Patients with Metabolic Syndrome; Investigator Initiated; Merck-Schering Plough (2009-2011)

Unraveling the Genetic Architecture of Very High HDL cholesterol through Transcriptome Analysis; NHLBI; R21 HL094980, 2009-2011

Comparative Effects of 2 Diets in Veterans with the Metabolic Syndrome; VA Merit Award, 2009-2013


Selected Publications:

Miller M, Mead L, Kwiterovich PO, Pearson TA. Dyslipidemias with desirable plasma total cholesterol levels and angiographically demonstrated coronary artery disease. Am J Cardiol 1990;65:1-5.

Miller M, Kwiterovich PO, Seidler A, Pearson TA. Long-term predictors of subsequent cardiovascular events with coronary artery disease and "desirable" levels of plasma total cholesterol. Circulation 1992;86:1165-1170.

Miller M, Kwiterovich PO, Bachorik PS, Georgopolous A. Decreased postprandial response to a fat meal in normotriglyceridemic men with hypoalphalipoproteinemia. Arterioscler Thromb 1993;13:385-92.

Miller M, Hutchins GM. Hemochromatosis, multiorgan hemosiderosis, and coronary artery disease. JAMA 1994;272(3):231-233.

Miller M, Zeller KI, Kwiterovich PO, Albers JJ, Feulner G. Lecithin: Cholesterol acyltransferase deficiency: identification of two defective alleles in fibroblast cDNA. J Lipid Res 1995;36:931-938.

Miller M, Zeller K. Alternative Splicing in Lecithin: Cholesterol Acyltransferase mRNA: An Evolutionary Paradigm in Humans and Great Apes. Gene 1997;190: 309-313.

Miller M, Seidler A, Moalemi A and Pearson TA. Normal triglyceride levels and coronary artery disease events: The Baltimore Coronary Observational Long-Term Study (COLTS).  J Am Coll Cardiol 1998; 31: 1252-1257.

Miller M, Aiello DB and Zeller KI. Apolipoprotein AI Zavalla (Leu159 --> Pro): HDL deficiency in a kindred associated with premature CAD. Arterioscler Thromb Vasc Biol 1998;18:1242-1247.

Miller M, Byington RP, Hunninghake D, Pitt B, Furberg C for the PREVENT Investigators. Gender bias and under-utilization of lipid lowering therapy in CAD patients at Academic U.S. and Canadian Medical Centers. Arch Intern Med  2000; 160: 343-347.

Miller M, Rhyne J, Khatta M, Parekh H, Zeller K. Prevalence of the APOC3 promoter polymorphisms T-455C and C-482T in Asian-Indians. Am J Cardiol 2001; 87: 220-221.

Hong SH, Rhyne J, Zeller K, Miller M. Novel ABCA1 compound variant associated with HDL cholesterol deficiency.  Biochim Biophys Acta 2002: 1587: 60-64.

Friend M, Vucenik I, Miller M. Reduced platelet responsiveness to aspirin in subjects with hyperlipidemia. BMJ. 2003;326(7380):82-3.

Hong SH, Rhyne J, Miller M. A Novel Polypyrimidine Variation [IVS46: del T –39…--46] in ABCA1 Causes Exon Skipping and Contributes to HDL Cholesterol Deficiency in a Family with Premature Coronary Disease. Circ Res. 2003;93:1006-1012

Miller M, Zhan M, Havas S.  High Attributable Risk of Elevated C-Reactive Protein to Conventional CHD Risk Factors: The NHANES III Study. Arch Intern Med 2005; 165:2063-8.

Miller M, Mangano C, Park Y, Goel R, Plotnick G, Vogel RA. Impact of Cinematic Viewing on Endothelial Function. Heart 2006; 92:261-2.

Rhyne J, Ryan MJ, White C, Himonas T, Miller M. The two novel CETP mutations Gln87X and Gln165X in a compound heterozygous state are associated with marked hyperalphalipoproteinemia and absence of significant coronary artery disease. J Mol Med 2006;84:647-650.

Miller M, Rhyne J, Chen H, Beach V, Ericson R, Luthra K, Dwivedi M, Misra A. The APOC3 promoter polymorphisms C-482T and T-455C are associated with the Metabolic Syndrome. Arch Med Res 2007; 38: 444-451.

Mantaring M, Rhyne J, Hong SH, Miller M. Genotypic variation in ABCA1 as contributors to the low and high HDL-C phenotype. Transl Res 2007; 149:205-210.

Miller M, Cannon C, Murphy SA, Qin J, Ray KK, Braunwald E, for the PROVE IT-TIMI 22 Investigators. Impact of triglyceride levels beyond low density lipoprotein cholesterol after an acute coronary syndrome in the PROVE IT-TIMI 22 Trial. J Am Coll Cardiol 2008; 51:724-730.

Pollin TI, Damcott CM, Shen H, Ott SH, Shelton J, Horenstein RB, Post W, McLenithan JC, Bielak LF, Peyser PA, Mitchell BD, Miller M, O'Connell JR, Shuldiner AR. A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and May Be Cardioprotective. Science 2008;322:1702-1705.

Rhyne J, Mantaring M, Gardner DF, Miller M. Multiple Splice Defects in ABCA1 cause Low HDL-C in a family with Hypoalphalipoproteinemia and Premature Coronary Disease. BMC Med Genet. 2009;10:1.

Miller M, Beach V, Sorkin JD, Mangano C, Dobmeier C, Novacic D, Rhyne J, Vogel RA. Comparative Effects of 3 Popular Diets on Lipids, Endothelial Function and C-Reactive Protein during Weight Maintenance. J Am Diet Assoc 2009; 109: 713-718.

Miller M, Fry WF. The effect of mirthful laughter on the human cardiovascular system. Med Hypotheses 2009; 73:636-639.

Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, Weissman NJ, Turco M. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009;361:2113-2122

Miller M, Mangano CC, Beach V, Kop WJ, Vogel RA. Divergent Effects of Joyful and Anxiety-Provoking Music on Endothelial Vasoreactivity. Psychosom Med. 2010;72:354-356.

Miller M. Hold the patty, not the lettuce: processing foods for over a quarter century in the Nurses' Health Study. Circulation. 2010;122:859-860.

Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM, Lennie TA, Levi M, Mazzone T, Pennathur S; on behalf of the American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Nursing, and Council on the Kidney in Cardiovascular Disease: Triglycerides and Cardiovascular Disease: A Scientific Statement from the American Heart Association. Circulation. 2011; 123:2292-2333.